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Background: Multidrug resistance (MDR) is a major hurdle for cancer treatment worldwide and accounts for
chemotherapy failure in over 90% of patients with metastatic cancer. Evidence of the cytotoxicity of Cameroonian
plants against cancer cell lines including MDR phenotypes is been intensively and progressively provided. The
present work was therefore designed to evaluate the cytotoxicity of the methanol extracts of twenty-two
Cameroonian medicinal plants against sensitive and MDR cancer cell lines.
Methods: The methanol maceration was used to obtain the crude plant extracts whilst the cytotoxicity of the
studied extracts was determined using a resazurin reduction assay.
Results: A preliminary assay on leukemia CCRF-CEM cells at 40 μg/mL shows that six of the twenty plant extract were
able to enhance less than 50% of the growth proliferation of CCRF-CEM cells. These include Crinum zeylanicum
(32.22%), Entada abyssinica (34.67%), Elaoephorbia drupifera (35.05%), Dioscorea bulbifera (45.88%), Eremomastax speciosa
(46.07%) and Polistigma thonningii (45.11%). Among these six plants, E. drupifera showed the best activity with IC50
values below or around 30 μg/mL against the nine tested cancer cell lines. The lowest IC50 value of 8.40 μg/mL was
recorded with the extract of E. drupifera against MDA-MB231 breast cancer cell line. The IC50 values below 10 μg/mL
were recorded with the extracts of E. drupifera against MDA-MB231 breast cancer cells, C. zeylanicum against HCT116
p53+/+ and HCT116p53-/- colon cancer cells and E. abyssinica against HCT116 p53+/+ cells.
Conclusion: The results of the present study provide evidence of the cytotoxic potential of some Cameroonian
medicinal plants and a baseline information for the potential use of Elaoephorbia drupifera in the treatment of sensitive
and drug-resistant cancer cell lines.
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The escape of cancer cells from chemotherapy by
multidrug resistance (MDR) mechanisms is until now a
major reason for systemic cancer treatment failure. So far,
limited progress has been made in the fight against MDR
cancer, and even the use of combination chemotherapy
cannot solve the problem [1,2]. Medicinal plants and alter-
native medicine are undeniable sources of new exploitable
active principles to manage infectious and degenerative* Correspondence: efferth@uni-mainz.de
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reproduction in any medium, provided the ordiseases. The structural diversity of chemicals from the
medicinal plants makes them valuable tools in the search
for potentially active drugs on sensitive and resistant
phenotypes. It is estimated that more than 60% of the
approved anticancer drugs in the United States of America
(from 1983 to 1994) were from natural origin [3,4]. In
Cameroon, medicinal plants are traditionally used to
manage infectious diseases and different types of cancers
[5]. Evidence of the cytotoxicity of these plants against
cancer cell lines has been provided [6-11]. In a recent re-
search program, we started to investigate the cytotoxicity of
Cameroonian plants against drug-resistant cancer cell lines.
The idea is to identify plants able to kill drug-resistanttd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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counterparts. Some of the plants identified so far include
Echinops giganteus, Imperata cylindrica, Piper capense and
Xylopia aethiopica which displayed considerable activities
against the P-glycoprotein-expressing adriamycin-resistant
cell line, CEM/ADR5000 [7,12]. This encourage us to
move forward to search for new cytotoxic agents from
Cameroonian medicinal plants, with emphasis on MDR
phenotypes with different mechanism of action. The
present work was therefore designed to evaluate the cyto-
toxicity of twenty-two Cameroonian plants against both
sensitive and drug-resistant cancer cell lines.
Methods
Plant material
All medicinal plants used in the present work were col-
lected at various locations of Dschang, West-Region of
Cameroon, between January and April 2012. The plants
were identified at the National Herbarium (Yaounde,
Cameroon), where voucher specimens were deposited
under the reference numbers indicated in Table 1. The
air-dried and powdered plant material was soaked in
methanol for 48 h, at room temperature. The methanol
extract was concentrated under reduced pressure to
give the crude extract. This extract was then conserved at
4°C until further use.
Extraction
The air-dried and powdered plant samples (1 kg) were
soaked in methanol (3 L) for 48 h, at room temperature.
The methanol extract was concentrated under vacuum to
give the crude extract. This extract was then conserved at
4°C until use.
Chemicals
Doxorubicin, vinblastine and daunorubicin were pro-
vided by the University Medical Center of the Johannes
Gutenberg University (Mainz, Germany) and dissolved
in PBS (Invitrogen, Eggenstein, Germany) at a concen-
tration of 10 mM. Geneticin was purchased from Sigma-
Aldrich (Munich, Germany) at a concentration of 50 mg/
mL in sterile-filtered H2O.
Cell cultures
Drug-sensitive CCRF-CEM and multidrug-resistant
CEM/ADR5000 leukemia cells were maintained in RPMI
1640 medium (Invitrogen) supplemented with 10% fetal
calf serum in a humidified 5% CO2 atmosphere at 37°C.
Sensitive and resistant cells were kindly provided by Dr.
Axel Sauerbrey (Department of Pediatrics, University of
Jena, Jena, Germany). The generation of the resistant
subline was previously described [52]. The specific
overexpression of P-glycorprotein, but not other ABC
transporters has been reported [53,54]. Breast cancercells, transduced with control vector (MDA-MB-231-
pcDNA3) or with cDNA for the breast cancer resistance
protein BCRP (MDA-MB-231-BCRP clone 23), were
maintained under standard conditions as described
above for CCRF-CEM cells. Human wild-type HCT116
(p53+/+) colon cancer cells as well as knockout clones
HCT116 (p53−/−) derived by homologous recombination
were a generous gift from Dr. B. Vogelstein and H.
Hermeking (Howard Hughes Medical Institute, Baltimore,
MD). Human glioblastoma multiforme U87MG cells
(non-transduced) and U87MG cell line transduced with
an expression vector harboring an epidermal growth
factor receptor (EGFR) gene with a genomic deletion of
exons 2 through 7 (U87MG.ΔEGFR) were kindly provided
by Dr. W. K. Cavenee (Ludwig Institute for Cancer
Research, San Diego, CA) [55]. MDA-MB-231-BCRP,
U87MG.ΔEGFR and HCT116 (p53−/−) were maintained
in DMEM medium containing 10% FBS (Invitrogen) and
1% penicillin (100 U/mL)-streptomycin (100 μg/mL)
(Invitrogen) and were continuously treated with 800
ng/mL and 400 μg/mL geneticin, respectively. Human
HepG2 hepatocellular carcinoma cells and normal
AML12 heptocytes were obtained from the American Type
Culture Collection (ATCC, USA). The above medium with-
out geneticin was used to maintain MDA-MB-231,
U87MG, HCT116 (p53+/+), HepG2 and AML12 cell lines.
The cells were passaged twice weekly. All experiments
were performed with cells in the logarithmic growth
phase.
Resazurin reduction assay
Resazurin reduction assay [56] was performed to assess
the cytotoxicity of the studied samples toward various sen-
sitive and resistant cancer cell lines. The assay is based on
the reduction of resazurin, to the highly fluorescent
resorufin by viable cells. Non-viable cells rapidly lose the
metabolic capacity to reduce resazurin and thus produce
no fluorescent signal. Briefly, adherent cells were detached
by treatment with 0.25% trypsin/EDTA (Invitrogen,
Darmstadt, Germany) and an aliquot of 1 × 104 cells was
placed in each well of a 96-well cell culture plate (Thermo
Scientific, Langenselbold, Germany) in a total volume of
200 μL. Cells were allowed to attach overnight and then
treated with different concentrations of the studied
sample. For suspension cells, aliquots of 2 × 104 cells per
well were seeded in 96-well-plates in a total volume of
100 μL. The studied sample was immediately added in
varying concentrations in an additional 100 μL of culture
medium to obtain a total volume of 200 μL/well. After
24 h or 48 h, 20 μL resazurin (Sigma-Aldrich, Schnelldorf,
Germany) 0.01% w/v in double-distilled water (ddH2O)
were added to each well and the plates incubated at 37°C
for 4 h. Fluorescence was measured on an Infinite M2000
Pro™ plate reader (Tecan, Crailsheim, Germany) using an
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aPlants were identified at the Cameroon National Herbarium (HNC); ICNA: Voucher with no identification code at the HNC; bThe percentage of the
methanol extract.
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length of 590 nm. Each assay was done at least two times,
with six replicate each. The viability was evaluated based on
a comparison with untreated cells. IC50 values represent
the sample’s concentrations required to inhibit 50% of cell
proliferation and were calculated from a calibration curve
by linear regression using Microsoft Excel.
Results and discussion
In a prescreening of twenty-two plants, we tested a single
concentration of 40 μg/mL for each sample against the
sensitive CCRF-CEM leukemia cell line. The results
depicted in Figure 1 indicate that six of the twenty-two
plant extracts were able to display less than 50% growthproliferation of CCRF-CEM cells. These include Crinum
zeylanicum (32.22%), Entada abyssinica (34.67%),
Elaoephorbia drupifera (35.05%), Dioscorea bulbifera
(45.88%), Eremomastax speciosa (46.07%) and Polistigma
thonningii (45.11%). The IC50 values of these samples were
then determined on a panel of cancer cell lines, including
both sensitive and MDR phenotypes. The results are
shown in Table 2. Only the Elaoephorbia drupifera extract
as well as the control drug doxorubucin inhibited the pro-
liferation of the nine studied cancer cell lines, with IC50
values below 40 μg/mL. Other extracts showed selective
activities, the IC50 values being obtained on 6/10 tested
cells lines for Crinum zeylanicum, 4/10 for Dioscorea








Figure 1 Growth percentage (%) of leukemia CCRF-CEM cancer cell line treated with plant extracts at 40 μg/mL and doxorubicin
(10 μg/mL).
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the criteria of the American National Cancer Institute, 30
μg/mL is the upper IC50 limit considered promising for
purification of a crude extract [57]. Consequently, the
highest concentration tested (40 μg/mL) in our screening
was slightly above this limit. Considering this cutoff point,
the IC50 values below or around 30 μg/mL were recorded
with only the E. drupifera extract against the nine tested
cancer cell lines (Table 2). However, other extract alsoTable 2 Cytotoxicity of the studied extracts towards sensitive
determined by the resazurin assay
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U87MG.ΔEGFR - 27.76 ± 1.86
(<0.69)
16.03 ± 0.88(0.68) -
Hep-G2 - - 23.23 ± 1.67 (1.72) -
AML12 - - - -
aThe degree of resistance (in brakets) was determined as the ratio of IC50 value of tdisplayed activities with IC50 values below 30 μg/mL on at
least one of the cancer cell line tested.
MDR is a major hurdle for cancer treatment worldwide
and accounts for chemotherapy failure in over 90% of pa-
tients with metastatic cancer [1,58]. In the present work,
we investigated both sensitive and MDR cell lines. The de-
grees of resistance were calculated by dividing the IC50
value of the resistant cell line by the corresponding paren-
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(ABCB1/MDR1) or breast cancer resistance protein
(ABCG2/BCRP). Furthermore, we tested a p53 knockout
cell line and a transfectant cell line harboring a mutation-
activated EGFR gene (ΔEGFR) as examples for resistance-
inducing tumor suppressors and oncogenes. Finally, we
investigated HepG2 liver cancer cells and AML12 normal
hepatocytes to compare carcinoma cells with normal cells.
The degree of resistance on the tested cell line toward the
control drug doxorubicin was generally high, showing that
the studied cell lines can obviously be considered as suit-
able cell models to study drug resistance. For the most
active extract E. drupifera, it can be observed that the de-
grees of resistance were in all cases lower than those of
doxorubicin, suggesting that this sample can be exploited
in a possible fight against cancer diseases involving MDR
phenotypes. In addition, collateral sensitivity (sample more
active on resistant cells than on sensitive cells) was observed
with the extract of E. drupifera against U87MG.ΔEGFR,
highlighting its good antiproliferative activity.
To the best of our knowledge, the cytotoxicity of the six
most active extracts (C. zeylanicum, D. bulbifera, E.
drupifera, E. abyssinica, E. speciosa and P. thonningii) is
being reported for the first time. Nevertheless, com-
pounds with activities against malignant cells such as
crinine, 6-hydroxybuphanidrine and 6-ethoxybuphanidrine
were isolated from C. zeylanicum [19]. Also, lupeol [27,28]
a moderately active cytotoxic compound [59] was identi-
fied in E. drupifera, the plant that displayed the best
activity as observed in this study. The presence of such
compounds could probably explain their antiproliferative
activity.Conclusion
In conclusion, the results of the present study provide evi-
dence of the cytotoxic potential of some Cameroonian
medicinal plants and highlight the good activity of
Elaoephorbia drupifera on sensitive and drug-resistant
cancer cell lines. This plant is a potential cytotoxic source,
that could be explored in more details in the future to
develop novel anticancer drugs against sensitive and re-
sistant phenotypes.
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